ING Groep NV Cuts Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

ING Groep NV trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 84.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 16,637 shares of the medical equipment provider’s stock after selling 90,246 shares during the quarter. ING Groep NV’s holdings in Zimmer Biomet were worth $1,796,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet in the 3rd quarter worth $28,000. Crewe Advisors LLC purchased a new stake in shares of Zimmer Biomet during the first quarter worth about $31,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet during the third quarter valued at about $31,000. Family Firm Inc. purchased a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Zimmer Biomet in the 2nd quarter worth approximately $43,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on ZBH. Evercore ISI decreased their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Truist Financial lifted their price target on Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a research report on Friday, November 1st. Robert W. Baird cut their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Raymond James decreased their target price on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Finally, BTIG Research dropped their target price on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research report on Thursday, October 3rd. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $123.22.

Zimmer Biomet Trading Up 3.4 %

ZBH stock opened at $112.54 on Friday. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90. The company’s 50-day simple moving average is $106.28 and its 200-day simple moving average is $110.11. The firm has a market cap of $22.40 billion, a P/E ratio of 21.40, a PEG ratio of 2.00 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period last year, the company earned $1.65 earnings per share. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.